Literatur
-
1
Orchard T R, Wordsworth B P, Jewell D P.
Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history.
Gut.
1998;
42
387-391 (IIb)
-
2
Bernstein C N, Blanchard J F, Rawsthorne P. et al .
The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Am J Gastroenterol.
2001;
96
1116-1122 (IIb)
-
3
Scarpa R, del P uente A, D’Arienzo A. et al .
The arthritis of ulcerative colitis: clinical and genetic aspects.
J Rheumatol.
1992;
19
373-377 (IIb)
-
4
de Vlam K, Mielants H, Cuvelier C. et al .
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.
J Rheumatol.
2000;
27
2860-2865 (IIb)
-
5
Palm O, Moum B, Jahnsen J. et al .
The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study).
Rheumatology (Oxford).
2001;
40
1256-1261 (IIb)
-
6
Jones G, Halbert J, Crotty M. et al .
The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials.
Rheumatology (Oxford).
2003;
42
6-13 (Ia)
-
7
Freitas J, Farricha V, Nascimento I. et al .
Rofecoxib: a possible cause of acute colitis.
J Clin Gastroenterol.
2002;
34
451-453 (IV)
-
8
Van Den Bosch F, Kruithof E, Baeten D. et al .
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
Arthritis Rheum.
2002;
46
755-765 (Ib)
-
9
Braun J, Brandt J, Listing J. et al .
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
Lancet.
2002;
359
1187-1193 (Ib)
-
10
Thomas P D, Keat A C, Forbes A. et al .
Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy.
Eur J Gastroenterol Hepatol.
1999;
11
1001-1005 (IIa)
-
11
Teixeira W G, da Silva J H, Teixeira M G. et al .
Pouchitis: extracolonic manifestation of ulcerative colitis?.
Rev Hosp Clin Fac Med Sao Paulo.
1999;
54
155-158 (III)
-
12
Lohmuller J L, Pemberton J H, Dozois R R. et al .
Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis.
Ann Surg.
1990;
211: 622 - 627; discussion 627 - 629 (III)
-
13
Olsson R, Danielsson A, Jarnerot G. et al .
Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.
Gastroenterology.
1991;
100
1319-1323 (IIb)
-
14
Parlak E, Kosar Y, Ulker A. et al .
Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey.
J Clin Gastroenterol.
2001;
33
299-301 (III)
-
15
Christodoulou D K, Katsanos K H, Kitsanou M. et al .
Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature.
Dig Liver Dis.
2002;
34
781-786 (III)
-
16
Kaya M, Angulo P, Lindor K D.
Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.
J Hepatol.
2000;
33
537-542 (III)
-
17
Boberg K M, Fausa O, Haaland T. et al .
Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis.
Hepatology.
1996;
23
1369-1376 (III)
-
18
van Buuren H R, van Hoogstraten H JE, Terkivatan T. et al .
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis.
J Hepatol.
2000;
33
543-548 (III)
-
19
Weber C, Krupski G, Lorenzen J. et al .
MRCP in primary sclerosing cholangitis.
Fortschr Röntgenstr.
2003;
-
20
Textor H J, Flacke S, Pauleit D. et al .
Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography.
Endoscopy.
2002;
34
984-990 (III)
-
21
Ferrara C, Valeri G, Salvolini L. et al .
Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children.
Pediatr Radiol.
2002;
32
413-417 (IIb)
-
22
Burak K W, Angulo P, Lindor K D.
Is there a role for liver biopsy in primary sclerosing cholangitis?.
Am J Gastroenterol.
2003;
98
1155-1158 (IIb)
-
23
Beuers U, Spengler U, Kruis W. et al .
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Hepatology.
1992;
16
707-714 (Ib)
-
24
Lindor K D.
Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.
N Engl J Med.
1997;
336
691-695 (Ib)
-
25
Harnois D M, Angulo P, Jorgensen R A. et al .
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Am J Gastroenterol.
2001;
96
1558-1562 (Ib)
-
26
Mitchell S A, Bansi D S, Hunt N. et al .
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Gastroenterology.
2001;
121
900-907 (Ib)
-
27
Baluyut A R, Sherman S, Lehman G A. et al .
Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.
Gastrointest Endosc.
2001;
53
308-312 (IIb)
-
28
Stiehl A, Rudolph G, Kloters-Plachky P. et al .
Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.
J Hepatol.
2002;
36
151-156 (IIb)
-
29
Tung B Y, Emond M J, Haggitt R C. et al .
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Ann Intern Med.
2001;
134
89-95 (IIb)
-
30
Pardi D S, Loftus E V Jr, Kremers W K. et al .
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Gastroenterology.
2003;
124
889-893 (III)
-
31
Boberg K M, Bergquist A, Mitchell S. et al .
Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.
Scand J Gastroenterol.
2002;
37
1205-1211 (III)
-
32
Gregory B, Ho V C.
Cutaneous manifestations of gastrointestinal disorders. Part II.
J Am Acad Dermatol.
1992;
26
371-383 (III)
-
33 Greenstein A J, Janowitz H D, Sachar D B. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore); 1976 55: 401-412 (III)
-
34
Tromm A, May D, Almus E. et al .
Hautmanifestationen bei chronisch entzündlichen Darmerkrankungen.
Z Gastroenterol.
2001;
39
137-144 (III)
-
35
Veloso F T, Carvalho J, Magro F.
Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients.
J Clin Gastroenterol.
1996;
23
29-34 (III)
-
36
Regueiro M, Valentine J, Plevy S. et al .
Infliximab for treatment of pyoderma gangraenosum associated with inflammatory bowel disease.
Am J Gastroenterol.
2003;
98
1821-1826 (IV)
-
37
Hughes A P, Jackson J M, Callen J P.
Clinical features and treatment of peristomal pyoderma gangraenosum.
Jama.
2000;
284
1546-1548 (IV)
-
38
Menachem Y, Gotsman I.
Clinical manifestations of pyoderma gangraenosum associated with inflammatory bowel disease.
Isr Med Assoc J.
2004;
6
88-90 (III)
-
39 Latkany P A, Jabs D A. Ocular manifestations of inflammatory bowel disease. In: Bayless TM, Hanauer SB. Advanced therapy of inflammatory bowel disease. London; B.C. Decker 2001: 275-277 (III)
-
40
Soukiasian S H, Foster C S, Raizman M B.
Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease.
Am J Ophthalmol.
1994;
118
601-611 (III)
-
41
de Vries J, Baarsma G S, Zaal M J. et al .
Cyclosporin in the treatment of severe chronic idiopathic uveitis.
Br J Ophthalmol.
1990;
74
344-349 (Ib)
-
42
Joseph A, Raj D, Dua H S. et al .
Infliximab in the treatment of refractory posterior uveitis.
Ophthalmology.
2003;
110
1449-1453 (IIb)
-
43
Bernstein C N, Leslie W D, Leboff M S.
AGA technical review on osteoporosis in gastrointestinal diseases.
Gastroenterology.
2003;
124
795-841 (Ia)
-
44
Ghosh S, Cowen S, Hannan W J. et al .
Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis.
Gastroenterology.
1994;
107
1031-1039 (IIb)
-
45
Reffitt D M, Meenan J, Sanderson J D. et al .
Bone density improves with disease remission in patients with inflammatory bowel disease.
Eur J Gastroenterol Hepatol.
2003;
15
1267-1273 (IIb)
-
46
Bernstein C N, Blanchard J F, Leslie W. et al .
The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study.
Ann Intern Med.
2000;
133
795-799 (IIb)
-
47
van Staa T P, Cooper C, Brusse L S. et al .
Inflammatory bowel disease and the risk of fracture.
Gastroenterology.
2003;
125
1591-1597 (IIb)
-
48
Vestergaard P, Krogh K, Rejnmark L. et al .
Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis.
Gut.
2000;
46
176-181 (IIa)
-
49
Marshall D, Johnell O, Wedel H.
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.
Bmj.
1996;
312
1254-1259 (Ia)
-
50
Andreassen H, Rungby J, Dahlerup J F. et al .
Inflammatory bowel disease and osteoporosis.
Scand J Gastroenterol.
1997;
32
1247-1255 (IV)
-
51
Vogelsang H, Klamert M, Resch H. et al .
Dietary vitamin D intake in patients with Crohn’s disease.
Wien Klin Wochenschr.
1995;
107
578-581 (IIb)
-
52
Bernstein C N, Seeger L L, Anton P A. et al .
A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study.
Aliment Pharmacol Ther.
1996;
10
777-786 (Ib)
-
53
Adachi J D, Ioannidis G.
Calcium and vitamin D therapy in corticosteroid-induced bone loss: what is the evidence?.
Calcif Tissue Int.
1999;
65
332-336 (Ia)
-
54
Buckley L M, Leib E S, Cartularo K S. et al .
Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med.
1996;
125
961-968 (Ib)
-
55
Adler G, Reinshagen M.
Extraintestinale Manifestationen.
Z Gastroenterol.
2003;
41
54-61 (IV)
Priv.-Doz. Dr. Max Reinshagen
Medizinische Klinik I, Städtisches Klinikum Braunschweig
Salzdahlumer Straße 90
38126 Braunschweig
Phone: ++ 49/5 31/5 95 24 30
Fax: ++ 49/5 31/5 95 26 53
Email: m.reinshagen@klinikum-braunschweig.de
